Company intelligence / Profile preview

RevBio

Lowell, Massachusetts, United Statesrevbio.com ↗

Ownership: Private
Development stage: Phase 1

Overview

RevBio’s TETRANITE® platform has demonstrated robust load-bearing capacity and rapid setting properties in preclinical studies. The company has initiated first-in-human clinical trials for cranial flap fixation with early patient enrollment and received FDA approval to expand these trials. A pivotal European trial for dental implant stabilization began in March 2025. Multiple NIH grants have been awarded to support these programs

Therapeutic areas: OtherNeurology
Modalities: DeviceBiologicRecombinant protein
Industry: Implantable Medical Devices

Drug pipeline

1 asset

TETRANITE

Phase 1

Indications: Cranial flap fixation, Dental implant stabilization

Partnerships

Pacific Dental Services (strategic investment/support of ongoing clinical trials)

Beyond the preview

Go deeper on RevBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RevBio.

Explore the full profile